POS-503 EVALUATING CHRONIC KIDNEY DISEASE PROGRESSION: A REPORT FROM THE DISCOVER CKD RETROSPECTIVE COHORT

• A. ABDUL SULTAN,
• H. Heerspink,
• M. Arnold,
• C. Pollock,
• J.J. Garcia Sanchez,
• J.J. Carrero,
• R. Pecoits-Filho,
• C. Lam,
• N. Kashihara,
• E. Kanda,
• M. Kosiborod,
• S. Fishbane,
• M. Lainscak,
• P. Stenvinkel,
• D.C. Wheeler

Affiliations

A. ABDUL SULTAN

AstraZeneca, None, Cambridge, United Kingdom

H. Heerspink

University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, Groningen, Netherlands

M. Arnold

AstraZeneca, None, Cambridge, United Kingdom

C. Pollock

Kolling Institute- Royal North Shore Hospital- University of Sydney, None, Sydney, Australia

J.J. Garcia Sanchez

AstraZeneca, None, Cambridge, United Kingdom

J.J. Carrero

Karolinska Institutet, Department of Medical Epidemiology and Biostatistics, Stockholm, Sweden

R. Pecoits-Filho

School of Medicine- Pontifícia Universidade Católica do Paraná, None, Curitiba, Brazil; Arbor Research Collaborative for Health, None, Ann Arbor, United States

C. Lam

National Heart Centre, None, Singapore, Singapore; Duke-NUS Medical School, None, Singapore, Singapore

N. Kashihara

Kawasaki Medical School, None, Kurashiki, Japan

E. Kanda

Kawasaki Medical School, None, Kurashiki, Japan

M. Kosiborod

Saint Luke's Mid America Heart Institute- University of Missouri-Kansas City, None, Kansas City, United States

S. Fishbane

Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Division of Nephrology, Hempstead, United States

M. Lainscak

Faculty of Medicine- University of Ljubljana, None, Ljubljana, Slovenia

P. Stenvinkel

Karolinska Institutet, Division of Renal Medicine, Stockholm, Sweden

D.C. Wheeler

University College London, Department of Renal Medicine, London, United Kingdom